const L126 = [
  {
    "id": 1,
    "category": "Folate Inhibitors: Mechanism of Action",
    "questionText": "A patient is given trimethoprim-sulfamethoxazole (TMP-SMX). The sulfonamide component is selectively toxic because it competes with the natural substrate para-aminobenzoic acid (PABA) at which bacterial enzyme?",
    "options": [
      {"text": "Dihydrofolate reductase (DHFR)", "explanation": "This is incorrect. DHFR is the target of the trimethoprim component in the second step of folate synthesis."},
      {"text": "DNA gyrase", "explanation": "This is incorrect. DNA gyrase is the target of fluoroquinolones."},
      {"text": "Dihydropteroate synthase (DHPS)", "explanation": "This is correct. Sulfonamides are structural analogs of PABA and competitively inhibit DHPS, the enzyme responsible for incorporating PABA into dihydrofolic acid, the first step in bacterial folate synthesis."},
      {"text": "Thymidylate synthase", "explanation": "This is incorrect. This enzyme uses the final product of the folate pathway."},
      {"text": "Glucose-6-phosphate dehydrogenase (G6PD)", "explanation": "This is incorrect. G6PD is a host enzyme relevant to sulfonamide toxicity, not its antibacterial mechanism."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0013.jpg"
  },
  {
    "id": 2,
    "category": "Folate Inhibitors: Mechanism of Action",
    "questionText": "TMP-SMX achieves synergy because the trimethoprim component blocks the conversion of dihydrofolate to active tetrahydrofolate, the second step in the folate pathway, by inhibiting which enzyme?",
    "options": [
      {"text": "Dihydropteroate synthase (DHPS)", "explanation": "This is incorrect. DHPS is the target of the sulfonamide component."},
      {"text": "Dihydrofolate reductase (DHFR)", "explanation": "This is correct. Trimethoprim is structurally similar to folic acid and inhibits bacterial DHFR, the enzyme that catalyzes the conversion of dihydrofolate to the active tetrahydrofolate."},
      {"text": "Cytochrome P450 (CYP)", "explanation": "This is incorrect. CYP is a host enzyme involved in metabolism, not the bacterial target."},
      {"text": "Methionine synthase", "explanation": "This is incorrect. This enzyme uses tetrahydrofolate as a cofactor."},
      {"text": "N-acetyltransferase (NAT2)", "explanation": "This is incorrect. NAT2 is a host enzyme involved in drug detoxification."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0013.jpg"
  },
  {
    "id": 3,
    "category": "Folate Inhibitors: Selectivity",
    "questionText": "Why does the sulfonamide component exhibit selective toxicity in bacterial cells over human host cells?",
    "options": [
      {"text": "Sulfonamides are rapidly metabolized by human CYPs.", "explanation": "This is incorrect. While metabolized, this is not the primary reason for selective toxicity."},
      {"text": "Sulfonamides stimulate the growth of human cells.", "explanation": "This is incorrect. Sulfonamides stimulate the growth of *Rickettsia*."},
      {"text": "Mammalian cells use exogenous folic acid from dietary sources.", "explanation": "This is correct. Humans obtain folic acid from their diet, bypassing the need for the *de novo* synthesis pathway (DHPS) that the sulfonamides block."},
      {"text": "Bacterial DHFR has a much higher affinity for trimethoprim.", "explanation": "This is incorrect. This is the reason for the selectivity of the *trimethoprim* component, not the sulfonamide component."},
      {"text": "Sulfonamides are effluxed from human cells via P-glycoprotein.", "explanation": "This is incorrect. This is not the mechanism of selective toxicity."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0013.jpg"
  },
  {
    "id": 4,
    "category": "Folate Inhibitors: PK/PD/Dosing",
    "questionText": "The combination of sulfamethoxazole (bacteriostatic) and trimethoprim (bacteriostatic) is often used because the sequential blockade of the folate pathway leads to what overall antibacterial effect?",
    "options": [
      {"text": "Antagonistic and Bactericidal", "explanation": "This is incorrect. The effect is synergistic, not antagonistic."},
      {"text": "Bacteriostatic, limiting resistance development", "explanation": "This is incorrect. The combination is bactericidal, and resistance still occurs."},
      {"text": "Synergistic and Bactericidal", "explanation": "This is correct. By blocking two successive steps (DHPS and DHFR) in the folate pathway, the TMP-SMX combination achieves a synergistic and bactericidal effect against susceptible organisms."},
      {"text": "Concentration-dependent killing", "explanation": "This is incorrect. This describes FQs and aminoglycosides."},
      {"text": "Time-dependent killing", "explanation": "This is incorrect. While it is time-dependent, the primary benefit is the synergy and bactericidal effect."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0026.jpg"
  },
  {
    "id": 5,
    "category": "Folate Inhibitors: PK/Dosing",
    "questionText": "Trimethoprim and sulfamethoxazole are paired together in a fixed 1:5 drug ratio because they share which crucial pharmacokinetic property?",
    "options": [
      {"text": "Both are eliminated mainly via biliary excretion.", "explanation": "This is incorrect. SMX is excreted mainly renally."},
      {"text": "They have similar half-lives, approximately 10-11 hours.", "explanation": "This is correct. Trimethoprim ($t\frac{1}{2} \approx 8-12$ hours) and sulfamethoxazole ($t\frac{1}{2} \approx 11$ hours) are paired due to their closely matching half-lives, which ensures the optimal synergistic 1:20 concentration ratio is maintained in the plasma."},
      {"text": "Both inhibit CYP2C9.", "explanation": "This is incorrect. While both are involved with CYP2C9 (SMX inhibits, TMP is a substrate), this is an adverse drug interaction, not the reason for their fixed pairing."},
      {"text": "Both are structural analogs of PABA.", "explanation": "This is incorrect. Trimethoprim is an analog of dihydrofolate, not PABA."},
      {"text": "Both are poorly absorbed from the GI tract.", "explanation": "This is incorrect. Both are rapidly and extensively absorbed."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0011.jpg"
  },
  {
    "id": 6,
    "category": "Folate Inhibitors: Adverse Effects",
    "questionText": "A patient on sulfamethoxazole develops hematuria and acute kidney injury. A urinalysis reveals crystalline deposits. What is the mechanism of this adverse effect?",
    "options": [
      {"text": "The drug is directly toxic to the renal tubular cells.", "explanation": "This is incorrect. While it causes damage, the unique mechanism for this toxicity is precipitation."},
      {"text": "Sulfonamides precipitate as crystals in acidic urine, causing obstruction.", "explanation": "This is correct. Sulfonamide drugs are weak acids whose solubility is reduced in acidic urine, leading to precipitation, crystal formation (crystalluria), and potentially obstruction and acute kidney injury."},
      {"text": "The drug inhibits the Epithelial Sodium Channel (ENaC), leading to hyperkalemia.", "explanation": "This is incorrect. This is the mechanism for trimethoprim's hyperkalemia."},
      {"text": "The drug causes Fanconi syndrome, leading to tubular dysfunction.", "explanation": "This is incorrect. Fanconi syndrome is linked to *outdated* tetracycline."},
      {"text": "The drug causes a displacement of creatinine from protein binding sites.", "explanation": "This is incorrect. This is not the mechanism of crystalluria."},
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0019.jpg"
  },
  {
    "id": 7,
    "category": "Folate Inhibitors: Adverse Effects",
    "questionText": "Sulfonamides are contraindicated in newborns and infants <2 months old. What is the mechanism of the potential life-threatening neurotoxicity (kernicterus) associated with this drug class?",
    "options": [
      {"text": "Sulfonamides displace unconjugated bilirubin from albumin, allowing it to deposit in the CNS.", "explanation": "This is correct. Sulfonamides compete with unconjugated bilirubin for plasma albumin binding sites. This increases the level of free bilirubin, which can cross the infant's immature blood-brain barrier and cause encephalopathy (kernicterus)."},
      {"text": "The drug causes dose-dependent inhibition of mitochondrial protein synthesis in the brain.", "explanation": "This is incorrect. This is a toxicity mechanism for chloramphenicol and linezolid."},
      {"text": "The drug inhibits DHFR in the neonate's brain cells.", "explanation": "This is incorrect. The drug has relative selectivity for bacterial DHFR."},
      {"text": "The drug causes an irreversible aplastic anemia in the neonate.", "explanation": "This is incorrect. Aplastic anemia is a rare, idiosyncratic toxicity that presents later."},
      {"text": "The drug inhibits the neonate's ability to excrete sulfonamide metabolites.", "explanation": "This is incorrect. While neonates have immature systems, the immediate cause of kernicterus is bilirubin displacement."},
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L126_page-0020.jpg"
  },
  {
    "id": 8,
    "category": "Folate Inhibitors: Adverse Effects",
    "questionText": "A patient with G6PD deficiency develops pallor, fatigue, and jaundice after starting sulfamethoxazole. What is the underlying mechanism of the acute hemolytic anemia?",
    "options": [
      {"text": "Sulfamethoxazole causes reversible bone marrow suppression.", "explanation": "This is incorrect. Bone marrow suppression is a later, different toxicity."},
      {"text": "Sulfonamides are oxidative agents that overwhelm the limited supply of NADPH in G6PD deficient red cells.", "explanation": "This is correct. In G6PD deficiency, erythrocytes cannot produce sufficient NADPH to maintain the defense against oxidative stress. Sulfonamides create reactive oxygen species, leading to acute hemolysis."},
      {"text": "The drug displaces hemoglobin from albumin binding sites.", "explanation": "This is incorrect. The drug displaces bilirubin, not hemoglobin."},
      {"text": "The drug induces methemoglobin formation.", "explanation": "This is incorrect. While sulfonamides can contribute to methemoglobinemia, the primary, potentially fatal, adverse effect is hemolytic anemia in this population."},
      {"text": "The drug stimulates antibody formation against the red blood cell membrane.", "explanation": "This is incorrect. This is a hypersensitivity reaction, not the core G6PD mechanism."},
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0018.jpg"
  },
  {
    "id": 9,
    "category": "Folate Inhibitors: Adverse Effects",
    "questionText": "A patient is identified as a 'slow acetylator' (polymorphism in the *NAT2* gene). This patient is at increased risk for which adverse reaction to sulfonamides?",
    "options": [
      {"text": "Crystalluria", "explanation": "This is incorrect. Crystalluria is related to urine pH and hydration."},
      {"text": "Hypertension", "explanation": "This is incorrect. This drug does not typically cause hypertension."},
      {"text": "Hypersensitivity reactions", "explanation": "This is correct. Slow acetylators metabolize sulfonamides less efficiently via the N-acetyltransferase pathway, leading to a build-up of reactive hydroxylamine and nitroso-sulfonamide metabolites, which increases the risk of hypersensitivity reactions."},
      {"text": "Megaloblastic anemia", "explanation": "This is incorrect. Megaloblastic anemia is related to folate inhibition, not N-acetylation status."},
      {"text": "Hyperkalemia", "explanation": "This is incorrect. Hyperkalemia is a toxicity of trimethoprim."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0012.jpg"
  },
  {
    "id": 10,
    "category": "Folate Inhibitors: Clinical Use (DOC)",
    "questionText": "TMP-SMX is the drug of choice for which severe opportunistic infection often seen in immunocompromised (HIV/AIDS) patients?",
    "options": [
      {"text": "C. difficile colitis", "explanation": "This is incorrect. Oral vancomycin or fidaxomicin are used for C. difficile."},
      {"text": "Tuberculosis", "explanation": "This is incorrect. TB requires a multi-drug regimen, but TMP-SMX is not typically a first-line agent."},
      {"text": "Pneumocystis pneumonia (*P. jirovecii*)", "explanation": "This is correct. TMP-SMX is the established drug of choice for the prevention and treatment of *Pneumocystis jirovecii* pneumonia (PCP)."},
      {"text": "*P. aeruginosa* VAP", "explanation": "This is incorrect. TMP-SMX is intrinsically resistant to *P. aeruginosa*."},
      {"text": "*Listeria* Meningitis", "explanation": "This is incorrect. Ampicillin plus gentamicin is the primary regimen for *Listeria* meningitis, though TMP-SMX is a preferred alternative."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0023.jpg"
  },
  {
    "id": 11,
    "category": "Folate Inhibitors: Clinical Use (Protozoa)",
    "questionText": "A patient with toxoplasmosis (caused by *T. gondii*) requires anti-protozoal therapy. The standard regimen combines a sulfonamide (sulfadiazine) with which DHFR inhibitor?",
    "options": [
      {"text": "Trimethoprim", "explanation": "This is incorrect. Trimethoprim is the DHFR inhibitor used for *bacterial* infections; pyrimethamine is used for *protozoal* infections."},
      {"text": "Mafenide", "explanation": "This is incorrect. Mafenide is a topical burn cream."},
      {"text": "Pyrimethamine", "explanation": "This is correct. Pyrimethamine is a potent DHFR inhibitor used with sulfadiazine for the first-line treatment of toxoplasmosis."},
      {"text": "Metronidazole", "explanation": "This is incorrect. Metronidazole is for anaerobic and other protozoal infections."},
      {"text": "Dapsone", "explanation": "This is incorrect. Dapsone is a sulfone used for leprosy and *Pneumocystis* prophylaxis, not toxoplasmosis treatment."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0023.jpg"
  },
  {
    "id": 12,
    "category": "Folate Inhibitors: Drug Interactions",
    "questionText": "Which agent used for prophylaxis of recurrent urinary tract infections is contraindicated with sulfonamides due to the risk of crystalline precipitate forming from formaldehyde?",
    "options": [
      {"text": "Methenamine", "explanation": "This is correct. Methenamine is a urinary antiseptic that is hydrolyzed to formaldehyde in acidic urine. Sulfonamides react with formaldehyde to form an insoluble precipitate, causing crystalluria and obstruction. The combination is contraindicated."},
      {"text": "Nitrofurantoin", "explanation": "This is incorrect. Nitrofurantoin is a urinary antiseptic, but the contraindication is with methenamine."},
      {"text": "Ciprofloxacin", "explanation": "This is incorrect. The interaction is chelation with divalent cations, not precipitation with formaldehyde."},
      {"text": "Trimethoprim", "explanation": "This is incorrect. This is the synergistic partner, not a contraindication."},
      {"text": "Doxycycline", "explanation": "This is incorrect. Doxycycline has chelation issues, not a formaldehyde interaction."},
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L126_page-0019.jpg"
  },
  {
    "id": 13,
    "category": "Folate Inhibitors: Clinical Use (Topical)",
    "questionText": "A patient with second-degree burns requires a topical cream that slowly releases silver to kill bacteria and yeast. Which agent is used?",
    "options": [
      {"text": "Mafenide acetate", "explanation": "This is incorrect. Mafenide acetate is absorbed and causes metabolic acidosis; it does not release silver."},
      {"text": "Sulfacetamide sodium", "explanation": "This is incorrect. Sulfacetamide sodium is used topically for ophthalmic and dermatologic infections."},
      {"text": "Silver sulfadiazine", "explanation": "This is correct. Silver sulfadiazine is a topical sulfonamide product used for burns that slowly releases silver, a broad-spectrum biocide, which is toxic to gram-positive, gram-negative bacteria, and yeast."},
      {"text": "Neomycin", "explanation": "This is incorrect. Neomycin is too toxic for parenteral use and is typically part of a triple antibiotic ointment."},
      {"text": "Sulfadoxine", "explanation": "This is incorrect. Sulfadoxine is a long-acting systemic sulfonamide used for malaria."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0015.jpg"
  },
  {
    "id": 14,
    "category": "Folate Inhibitors: Adverse Effects (Topical)",
    "questionText": "Which topical burn preparation is readily absorbed from the wound, is a carbonic anhydrase inhibitor, and is known to cause metabolic acidosis?",
    "options": [
      {"text": "Silver sulfadiazine", "explanation": "This is incorrect. Silver sulfadiazine is poorly absorbed and does not inhibit carbonic anhydrase."},
      {"text": "Sulfacetamide sodium", "explanation": "This is incorrect. This is an ophthalmic/dermatological agent."},
      {"text": "Mafenide acetate", "explanation": "This is correct. Mafenide is rapidly absorbed from the burn surface and is a carbonic anhydrase inhibitor, which leads to bicarbonate loss in the urine and metabolic acidosis."},
      {"text": "Neomycin", "explanation": "This is incorrect. Neomycin is not a sulfonamide and is too toxic for parenteral use."},
      {"text": "Sulfadiazine", "explanation": "This is incorrect. Sulfadiazine is a systemic sulfonamide used in combination for toxoplasmosis."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0015.jpg"
  },
  {
    "id": 15,
    "category": "Folate Inhibitors: Drug Interactions",
    "questionText": "A diabetic patient on glyburide (sulfonylurea) for type 2 diabetes begins TMP-SMX and develops profound hypoglycemia. What is the mechanism of this drug interaction?",
    "options": [
      {"text": "Trimethoprim inhibits ENaC, reducing the metabolism of glyburide.", "explanation": "This is incorrect. Trimethoprim inhibits ENaC, but sulfamethoxazole causes the metabolic inhibition."},
      {"text": "Sulfamethoxazole displaces glyburide from plasma proteins and inhibits its metabolism (CYP2C9).", "explanation": "This is correct. Sulfonamides displace drugs with narrow therapeutic windows, like sulfonylureas, from plasma proteins and inhibit their metabolism via CYP2C9, leading to enhanced hypoglycemic effects."},
      {"text": "Trimethoprim directly causes hypoglycemia by inhibiting glucose reabsorption.", "explanation": "This is incorrect. This is not the mechanism."},
      {"text": "Both drugs enhance the synthesis of Vitamin K, leading to hypercoagulation.", "explanation": "This is incorrect. Both drugs increase bleeding risk, but not through this mechanism."},
      {"text": "Blockade of Epithelial Sodium Channel (ENaC) and competition for albumin binding", "explanation": "This is incorrect. ENaC blockade causes hyperkalemia, which is unrelated to the warfarin interaction."},
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0011.jpg"
  },
  {
    "id": 16,
    "category": "Folate Inhibitors: PK/Non-ABX Use",
    "questionText": "Which sulfonamide derivative is poorly absorbed from the GI tract, but is metabolized by gut flora into sulfapyridine and mesalamine (5-ASA) to treat inflammatory bowel disease and rheumatoid arthritis?",
    "options": [
      {"text": "Sulfadiazine", "explanation": "This is incorrect. Sulfadiazine is rapidly absorbed and used systemically for toxoplasmosis."},
      {"text": "Sulfamethoxazole", "explanation": "This is incorrect. Sulfamethoxazole is rapidly absorbed and used systemically in TMP-SMX."},
      {"text": "Sulfasalazine", "explanation": "This is correct. Sulfasalazine is poorly absorbed, allowing it to act locally. It is cleaved by intestinal flora into sulfapyridine (systemic RA effect) and mesalamine (local IBD effect)."},
      {"text": "Sulfacetamide", "explanation": "This is incorrect. Sulfacetamide is used topically for ophthalmic and dermatologic infections."},
      {"text": "Sulfadoxine", "explanation": "This is incorrect. Sulfadoxine is a long-acting systemic agent for malaria."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0011.jpg"
  },
  {
    "id": 17,
    "category": "Folate Inhibitors: Adverse Effects",
    "questionText": "Trimethoprim can cause hyperkalemia, especially in patients with renal impairment. This effect is due to trimethoprim inhibiting which receptor/channel in the kidney?",
    "options": [
      {"text": "Aldosterone receptor", "explanation": "This is incorrect. Trimethoprim is not an aldosterone receptor antagonist."},
      {"text": "Epithelial sodium channel (ENaC)", "explanation": "This is correct. Trimethoprim is structurally similar to the potassium-sparing diuretic amiloride and can inhibit ENaC in the collecting ducts, leading to impaired sodium reabsorption and decreased potassium excretion, causing hyperkalemia."},
      {"text": "Na+/K+-ATPase pump", "explanation": "This is incorrect. This is the target of digoxin."},
      {"text": "Carbonic anhydrase", "explanation": "This is incorrect. This is inhibited by mafenide acetate."},
      {"text": "Vasopressin (ADH) receptor", "explanation": "This is incorrect. This is inhibited by demeclocycline."},
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0030.jpg"
  },
  {
    "id": 18,
    "category": "Folate Inhibitors: Resistance",
    "questionText": "One mechanism of acquired resistance to sulfonamides involves bacteria increasing the production of which precursor molecule to outcompete the drug at the DHPS binding site?",
    "options": [
      {"text": "Pteridine precursor", "explanation": "This is incorrect. PABA is the competitive substrate."},
      {"text": "Glutamate", "explanation": "This is incorrect. Glutamate combines later in the pathway."},
      {"text": "Para-aminobenzoic acid (PABA)", "explanation": "This is correct. The sulfonamides are competitive inhibitors of PABA. Resistance can arise when bacteria enhance PABA production, which outcompetes the drug at the DHPS binding site."},
      {"text": "Tetrahydrofolic acid", "explanation": "This is incorrect. This is the final active product."},
      {"text": "DHFR", "explanation": "This is incorrect. DHFR is the target of trimethoprim, not the precursor to sulfonamide resistance."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0014.jpg"
  },
  {
    "id": 19,
    "category": "Folate Inhibitors: Resistance",
    "questionText": "Which group of microorganisms is intrinsically resistant to sulfonamides because they utilize exogenous folic acid from the dietary source and therefore lack the DHPS enzyme target?",
    "options": [
      {"text": "Aerobic Gram-negative bacilli", "explanation": "This is incorrect. Sulfonamides are active against many GNBs."},
      {"text": "Obligate anaerobes", "explanation": "This is incorrect. While intrinsically resistant, it's not due to using exogenous folate."},
      {"text": "Enterococci", "explanation": "This is correct. *Enterococci* and other bacteria that utilize pre-formed exogenous folic acid are intrinsically resistant to sulfonamides because they bypass the DHPS step that sulfonamides inhibit."},
      {"text": "Mycobacterium tuberculosis", "explanation": "This is incorrect. *Mycobacterium* is intrinsically resistant due to cell wall impermeability."},
      {"text": "Nocardia", "explanation": "This is incorrect. Nocardia is generally susceptible and TMP-SMX is the drug of choice."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0014.jpg"
  },
  {
    "id": 20,
    "category": "Folate Inhibitors: Clinical Use",
    "questionText": "Trimethoprim monotherapy is rarely used systemically except for which two applications?",
    "options": [
      {"text": "Treatment of toxoplasmosis and severe acne", "explanation": "This is incorrect. Toxoplasmosis requires pyrimethamine, and severe acne requires long-term topical/oral therapy."},
      {"text": "Treatment of plague and anthrax", "explanation": "This is incorrect. These are treated with streptomycin/gentamicin or fluoroquinolones."},
      {"text": "Prophylaxis of UTI and *Pneumocystis* pneumonia (with dapsone)", "explanation": "This is correct. Trimethoprim monotherapy is used for uncomplicated urinary tract infection (UTI) prophylaxis and in combination with dapsone for *Pneumocystis* pneumonia prophylaxis."},
      {"text": "Monotherapy for severe systemic *E. coli* infections", "explanation": "This is incorrect. Monotherapy is avoided for systemic infections due to resistance and bacteriostatic action."},
      {"text": "Treatment of inflammatory bowel disease and rheumatoid arthritis", "explanation": "This is incorrect. This is the use for sulfasalazine."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0022.jpg"
  },
  {
    "id": 21,
    "category": "Folate Inhibitors: Adverse Effects",
    "questionText": "The hematopoietic adverse effects (megaloblastic anemia, leukopenia, granulocytopenia) of trimethoprim are often reversible by co-administering which nutrient?",
    "options": [
      {"text": "Iron supplements", "explanation": "This is incorrect. Iron treats iron-deficiency anemia, which is a different etiology."},
      {"text": "Vitamin B12", "explanation": "This is incorrect. Vitamin B12 deficiency leads to megaloblastic anemia, but trimethoprim directly inhibits folate metabolism."},
      {"text": "Folic acid/Leucovorin", "explanation": "This is correct. Trimethoprim causes megaloblastic anemia by inhibiting folate metabolism. This toxicity can be prevented or treated with supplemental folic acid (leucovorin) because host DHFR is less sensitive to trimethoprim than the bacterial enzyme."},
      {"text": "N-acetylcysteine (NAC)", "explanation": "This is incorrect. NAC is used to replenish glutathione stores."},
      {"text": "Vitamin K", "explanation": "This is incorrect. Vitamin K is related to clotting factors and warfarin interaction."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0007.jpg"
  },
  {
    "id": 22,
    "category": "Folate Inhibitors: Adverse Effects",
    "questionText": "Which rare, idiosyncratic, and potentially fatal adverse effect of sulfonamides occurs *without* prior dose-related myelosuppression and is often irreversible?",
    "options": [
      {"text": "Acute hemolytic anemia (in G6PD deficiency)", "explanation": "This is incorrect. Hemolytic anemia is dose-related in G6PD patients."},
      {"text": "Megaloblastic anemia (due to folate depletion)", "explanation": "This is incorrect. Megaloblastic anemia is predictable and dose-related."},
      {"text": "Crystalluria (due to precipitation in urine)", "explanation": "This is incorrect. Crystalluria is dose-related and mechanically induced."},
      {"text": "Idiosyncratic aplastic anemia", "explanation": "This is correct. Idiosyncratic aplastic anemia is a serious, rare adverse effect of sulfonamides (and chloramphenicol) that is typically irreversible and deadly, occurring spontaneously without warning."},
      {"text": "Toxic epidermal necrolysis (TEN)", "explanation": "This is incorrect. TEN is a severe hypersensitivity reaction, not an idiosyncratic hematopoietic effect."},
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L126_page-0016.jpg"
  },
  {
    "id": 23,
    "category": "Folate Inhibitors: Adverse Effects",
    "questionText": "Long-term use of trimethoprim monotherapy for UTI prophylaxis can lead to what condition, resulting from inhibition of folate metabolism?",
    "options": [
      {"text": "Irreversible neurotoxicity", "explanation": "This is incorrect. This is not a known toxicity of trimethoprim."},
      {"text": "Idiosyncratic aplastic anemia", "explanation": "This is incorrect. Aplastic anemia is a rare, idiosyncratic event, not a predictable result of antifolate action."},
      {"text": "Megaloblastic anemia", "explanation": "This is correct. Trimethoprim's predictable adverse effects result from inhibiting bacterial *and* human DHFR, which can manifest as megaloblastic anemia, especially with large doses or long-term use in patients with pre-existing folate deficiency."},
      {"text": "Nephrogenic diabetes insipidus", "explanation": "This is incorrect. This is a toxicity of demeclocycline."},
      {"text": "Hemolytic anemia", "explanation": "This is incorrect. Hemolytic anemia is primarily linked to G6PD deficiency."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0007.jpg"
  },
  {
    "id": 24,
    "category": "Folate Inhibitors: Drug Interactions",
    "questionText": "What two distinct mechanisms contribute to the enhanced risk of bleeding when sulfamethoxazole is co-administered with warfarin?",
    "options": [
      {"text": "Inhibition of P-glycoprotein and reduction in platelet count", "explanation": "This is incorrect. P-glycoprotein inhibition is not the primary mechanism, and thrombocytopenia is a rare side effect."},
      {"text": "Inhibition of CYP2C9 and elimination of gut microbiota that produce Vitamin K", "explanation": "This is correct. Sulfamethoxazole inhibits the metabolism of warfarin via CYP2C9 and eliminates vitamin K-producing gut microbiota, both of which augment warfarin's anticoagulant effect, leading to an increased risk of excessive bleeding."},
      {"text": "Inhibition of DHFR and competition for plasma protein binding", "explanation": "This is incorrect. While competition for plasma protein binding occurs, inhibition of DHFR is not directly linked to the enhanced warfarin effect."},
      {"text": "Stimulation of fibrinolysis and displacement of Factor X", "explanation": "This is incorrect. This is not the mechanism."},
      {"text": "Blockade of Epithelial Sodium Channel (ENaC) and competition for albumin binding", "explanation": "This is incorrect. ENaC blockade causes hyperkalemia, which is unrelated to the warfarin interaction."},
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0011.jpg"
  },
  {
    "id": 25,
    "category": "Folate Inhibitors: Adverse Effects (Metabolism)",
    "questionText": "The severe dermatologic (e.g., Stevens-Johnson syndrome) and hepatic adverse effects of sulfonamides are primarily caused by accumulation of what molecules?",
    "options": [
      {"text": "N4-Acetyl Sulfonamide (nontoxic metabolite)", "explanation": "This is incorrect. This metabolite is nontoxic and readily excreted."},
      {"text": "Sulfonamide hydroxylamine and nitroso-sulfonamide (reactive metabolites)", "explanation": "This is correct. Sulfonamides are metabolized via N-oxidation to highly reactive hydroxylamine and nitroso-sulfonamide metabolites. Accumulation of these molecules (due to slow acetylation or glutathione depletion) leads to direct cytotoxicity and protein haptenation, causing hypersensitivity reactions."},
      {"text": "Unconjugated bilirubin", "explanation": "This is incorrect. Bilirubin accumulation causes kernicterus, not rashes/hepatitis."},
      {"text": "Thymidine and purines", "explanation": "This is incorrect. Folate inhibitors block the synthesis of these, but they do not cause toxicity."},
      {"text": "Reactive oxygen species (ROS)", "explanation": "This is incorrect. While oxidative stress is involved, the specific molecules are the reactive metabolites."},
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0012.jpg"
  },
  {
    "id": 26,
    "category": "Folate Inhibitors: Clinical Use",
    "questionText": "TMP-SMX is the preferred alternative therapy for severe *Listeria monocytogenes* infections, including meningitis. This is due to its synergy and bactericidal activity, reaching which location?",
    "options": [
      {"text": "Extracellular fluid", "explanation": "This is incorrect. While they reach ECF, the key sites are CSF and intracellular spaces."},
      {"text": "Intracellular cytoplasm", "explanation": "This is incorrect. While it is active intracellularly, the key factor for *meningitis* is CSF penetration."},
      {"text": "Cerebrospinal fluid (CSF)", "explanation": "This is correct. TMP-SMX is the preferred alternative for *Listeria* meningitis because it achieves adequate concentrations in the CSF and is bactericidal to *Listeria*."},
      {"text": "Biliary system", "explanation": "This is incorrect. The biliary system is the excretion route for doxycycline."},
      {"text": "Bone marrow", "explanation": "This is incorrect. Bone marrow is where its toxicity occurs."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0027.jpg"
  },
  {
    "id": 27,
    "category": "Folate Inhibitors: Adverse Effects",
    "questionText": "The hematopoietic effects (megaloblastic anemia, leukopenia) of trimethoprim are often reversible by co-administering which nutrient?",
    "options": [
      {"text": "Folic acid/Leucovorin", "explanation": "This is correct. Trimethoprim inhibits folate metabolism, leading to a deficiency. Supplementing with active folate (leucovorin) or folic acid can prevent or reverse these predictable hematopoietic effects."},
      {"text": "Vitamin B12", "explanation": "This is incorrect. B12 deficiency is a different etiology of megaloblastic anemia."},
      {"text": "Iron supplements", "explanation": "This is incorrect. Iron treats microcytic anemia."},
      {"text": "Vitamin K", "explanation": "This is incorrect. Vitamin K is related to clotting factors."},
      {"text": "N-acetylcysteine (NAC)", "explanation": "This is incorrect. NAC is used to replenish glutathione stores."},
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L126_page-0007.jpg"
  },
  {
    "id": 28,
    "category": "Folate Inhibitors: PK",
    "questionText": "Which long-acting sulfonamide has a half-life of 5-9 days and is used in combination with pyrimethamine for malaria treatment?",
    "options": [
      {"text": "Sulfamethoxazole", "explanation": "This is incorrect. Sulfamethoxazole has a half-life of 11 hours."},
      {"text": "Sulfadiazine", "explanation": "This is incorrect. Sulfadiazine has a half-life of 10 hours."},
      {"text": "Sulfisoxazole", "explanation": "This is incorrect. Sulfisoxazole has a half-life of 5-6 hours."},
      {"text": "Sulfadoxine", "explanation": "This is correct. Sulfadoxine is classified as a long-acting sulfonamide with a half-life of 5-9 days, used in combination with pyrimethamine to treat *Plasmodium falciparum* malaria."},
      {"text": "Sulfasalazine", "explanation": "This is incorrect. Sulfasalazine has a poor absorption rate and is used for IBD/RA."},
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L126_page-0011.jpg"
  },
  {
    "id": 29,
    "category": "Folate Inhibitors: Resistance",
    "questionText": "Why should sulfonamides never be used to treat Rickettsial infections (like RMSF)?",
    "options": [
      {"text": "Sulfonamides stimulate the growth of Rickettsia.", "explanation": "This is correct. Sulfonamides are contraindicated in Rickettsial infections because they are known to stimulate the growth of Rickettsia."},
      {"text": "Rickettsia is intrinsically resistant due to lack of a cell wall.", "explanation": "This is incorrect. Rickettsia is an atypical intracellular organism, but stimulation of growth is the specific contraindication."},
      {"text": "The drugs cause irreversible optic nerve damage in this setting.", "explanation": "This is incorrect. This is a toxicity of streptomycin."},
      {"text": "Rickettsia expresses the DHFR enzyme with high affinity for sulfonamides.", "explanation": "This is incorrect. Sulfonamides inhibit DHPS, not DHFR."},
      {"text": "Rickettsia is anaerobic and lacks the transport system.", "explanation": "This is incorrect. Rickettsia is not anaerobic."},
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L126_page-0014.jpg"
  },
  {
    "id": 30,
    "category": "Folate Inhibitors: Clinical Use (Topical)",
    "questionText": "Which topical burn cream acts by inhibiting carbonic anhydrase and is known to cause intense pain upon application?",
    "options": [
      {"text": "Silver sulfadiazine", "explanation": "This is incorrect. Silver sulfadiazine does not inhibit carbonic anhydrase."},
      {"text": "Sulfacetamide sodium", "explanation": "This is incorrect. Sulfacetamide sodium is not used for large burn areas."},
      {"text": "Mafenide acetate", "explanation": "This is correct. Mafenide is readily absorbed from the burn area, and both the drug and its metabolite inhibit carbonic anhydrase, leading to metabolic acidosis. It also causes intense pain upon application."},
      {"text": "Neomycin", "explanation": "This is incorrect. Neomycin is too toxic for parenteral use."},
      {"text": "Sulfadiazine", "explanation": "This is incorrect. Sulfadiazine is a systemic sulfonamide."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0015.jpg"
  },
  {
    "id": 31,
    "category": "Fluoroquinolones: Mechanism of Action",
    "questionText": "Fluoroquinolones interfere with bacterial DNA synthesis by forming a ternary complex that inhibits which two bacterial enzymes?",
    "options": [
      {"text": "DNA polymerase and Thymidylate synthase", "explanation": "This is incorrect. These enzymes are involved in replication and synthesis but are not the primary FQ targets."},
      {"text": "RNA polymerase and Peptidyl transferase", "explanation": "This is incorrect. RNA polymerase is the target of rifamycins, and peptidyl transferase is the target of macrolides/chloramphenicol."},
      {"text": "DNA gyrase and Topoisomerase IV", "explanation": "This is correct. FQs form a ternary complex that inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, leading to DNA double-strand breaks and cell death."},
      {"text": "Dihydrofolate reductase (DHFR) and Dihydropteroate synthase (DHPS)", "explanation": "This is incorrect. These are the targets of trimethoprim and sulfonamides."},
      {"text": "N-acetylglucosamine and N-acetylmuramic acid", "explanation": "This is incorrect. These are cell wall precursors targeted by beta-lactams and glycopeptides."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0044.jpg"
  },
  {
    "id": 32,
    "category": "Fluoroquinolones: Mechanism of Action",
    "questionText": "DNA gyrase is the primary FQ target in which group of bacteria, while topoisomerase IV is the primary target in the other group?",
    "options": [
      {"text": "DNA Gyrase in Gram-positives; Topo IV in Gram-negatives", "explanation": "This is incorrect. The roles are generally reversed."},
      {"text": "DNA Gyrase in Mycobacteria; Topo IV in Spirochetes", "explanation": "This is incorrect. This generalization applies to the overall Gram stain characteristic."},
      {"text": "DNA Gyrase in Gram-negatives; Topo IV in Gram-positives", "explanation": "This is correct. DNA gyrase is the primary target in Gram-negative bacteria, while Topoisomerase IV is believed to be the primary target in many Gram-positive bacteria."},
      {"text": "DNA Gyrase in Anaerobes; Topo IV in Aerobes", "explanation": "This is incorrect. FQs are generally not useful for anaerobes."},
      {"text": "DNA Gyrase in Atypicals; Topo IV in Enterobacterales", "explanation": "This is incorrect. Atypicals lack the cell wall structure to support this generalization."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0038.jpg"
  },
  {
    "id": 33,
    "category": "Fluoroquinolones: Mechanism of Action",
    "questionText": "Inhibition of topoisomerase IV by fluoroquinolones specifically blocks which critical step in the replication of circular bacterial DNA?",
    "options": [
      {"text": "Re-ligation of double-strand breaks by DNA gyrase", "explanation": "This is incorrect. This is the mechanism of DNA Gyrase inhibition (the primary target in G-)."},
      {"text": "The formation of negative supercoils ahead of the replication fork", "explanation": "This is incorrect. This is the normal function of DNA gyrase."},
      {"text": "Decatenation, the separation of replicated chromosomal DNA during cell division", "explanation": "This is correct. Topoisomerase IV's primary role is decatenation (separating daughter chromosomes). FQs interfere with this process."},
      {"text": "The entry of the drug across the outer membrane via porins", "explanation": "This is incorrect. This is a pharmacokinetic step related to resistance."},
      {"text": "The irreversible binding to the 30S ribosomal subunit", "explanation": "This is incorrect. This is the mechanism of aminoglycosides."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0044.jpg"
  },
  {
    "id": 34,
    "category": "Fluoroquinolones: Pharmacokinetics (Interactions)",
    "questionText": "A patient is prescribed ciprofloxacin. What common dietary supplements/medications must be separated by at least 2 hours to prevent reduced ciprofloxacin absorption?",
    "options": [
      {"text": "Antihypertensives (ACE inhibitors)", "explanation": "This is incorrect. This class does not chelate the FQ."},
      {"text": "Antacids and products containing di- or trivalent cations (e.g., iron, calcium, magnesium)", "explanation": "This is correct. The oral absorption of FQs is impaired by di- and trivalent cations, which chelate the drug and must be separated by at least 2 hours."},
      {"text": "Glucocorticoids", "explanation": "This is incorrect. Glucocorticoids increase the risk of tendon rupture, but do not reduce absorption."},
      {"text": "Folic acid supplements", "explanation": "This is incorrect. This does not chelate the FQ."},
      {"text": "Theophylline", "explanation": "This is incorrect. Theophylline is affected by CYP1A2 inhibition, but does not reduce ciprofloxacin absorption."},
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0050.jpg"
  },
  {
    "id": 35,
    "category": "Fluoroquinolones: Pharmacokinetics (Renal Excretion)",
    "questionText": "Levofloxacin is 87% renally excreted as unchanged drug. What is the most important clinical relevance of this high renal excretion percentage?",
    "options": [
      {"text": "It requires concomitant administration of Probenecid.", "explanation": "This is incorrect. Probenecid blocks tubular secretion of drugs, but is not routinely used with FQs."},
      {"text": "It increases the risk of tendon rupture.", "explanation": "This is incorrect. Tendon rupture is a risk factor, not a result of the high renal excretion rate."},
      {"text": "Dosage must be adjusted in patients with renal impairment.", "explanation": "This is correct. The clinical relevance of a high renal excretion rate is that the drug will accumulate and cause toxicity if the kidney function is impaired, necessitating dose adjustment."},
      {"text": "It is preferred for treating *P. aeruginosa* infections.", "explanation": "This is incorrect. Its broad spectrum, not its renal excretion, makes it effective against *P. aeruginosa*."},
      {"text": "It has a high risk of causing megaloblastic anemia.", "explanation": "This is incorrect. This is a toxicity of trimethoprim."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0041.jpg"
  },
  {
    "id": 36,
    "category": "Fluoroquinolones: Pharmacokinetics (Exception)",
    "questionText": "Moxifloxacin achieves a low concentration of active drug in the urine compared to other FQs. What is the clinical relevance?",
    "options": [
      {"text": "It is the only FQ that requires dose adjustment in renal failure.", "explanation": "This is incorrect. Most FQs require renal dose adjustment."},
      {"text": "It is preferred for treating urinary tract infections.", "explanation": "This is incorrect. It is *not* preferred for UTIs due to low urine concentration."},
      {"text": "It is less nephrotoxic than other FQs.", "explanation": "This is incorrect. All FQs carry risk."},
      {"text": "It is not the preferred agent for treating urinary tract infections (UTIs).", "explanation": "This is correct. High urine concentration is essential for UTI treatment; because moxifloxacin is mainly hepatically eliminated, it achieves low concentrations in the urine and is generally not used for UTIs."},
      {"text": "It is the only FQ with activity against *P. aeruginosa*.", "explanation": "This is incorrect. Ciprofloxacin and levofloxacin also cover *P. aeruginosa*."},
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L126_page-0041.jpg"
  },
  {
    "id": 37,
    "category": "Fluoroquinolones: Spectrum (MRSA)",
    "questionText": "Which next-generation fluoroquinolone has improved activity against gram-positive organisms, including MRSA?",
    "options": [
      {"text": "Ciprofloxacin", "explanation": "This is incorrect. Ciprofloxacin has moderate activity against gram-positives, but not MRSA."},
      {"text": "Levofloxacin", "explanation": "This is incorrect. Levofloxacin has enhanced gram-positive activity, but not MRSA coverage."},
      {"text": "Moxifloxacin", "explanation": "This is incorrect. Moxifloxacin has improved gram-positive activity but not MRSA coverage."},
      {"text": "Delafloxacin", "explanation": "This is correct. Delafloxacin is the only fluoroquinolone with activity against MRSA."},
      {"text": "Nalidixic acid", "explanation": "This is incorrect. Nalidixic acid is a first-generation quinolone for UTIs only."},
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L126_page-0046.jpg"
  },
  {
    "id": 38,
    "category": "Fluoroquinolones: Spectrum (Anaerobe)",
    "questionText": "Which fluoroquinolone is the *only* one with specific anaerobic activity, making it useful for anaerobic lung infections and abscesses?",
    "options": [
      {"text": "Ciprofloxacin", "explanation": "This is incorrect. Ciprofloxacin lacks reliable anaerobic coverage."},
      {"text": "Levofloxacin", "explanation": "This is incorrect. Levofloxacin lacks reliable anaerobic coverage."},
      {"text": "Moxifloxacin", "explanation": "This is correct. Moxifloxacin is the only FQ that possesses reliable anaerobic activity, making it useful for infections like lung abscesses and aspiration pneumonia."},
      {"text": "Delafloxacin", "explanation": "This is incorrect. Delafloxacin covers MRSA, but is not specifically noted as the only one with anaerobic activity."},
      {"text": "Ofloxacin", "explanation": "This is incorrect. Ofloxacin lacks reliable anaerobic coverage."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0046.jpg"
  },
  {
    "id": 39,
    "category": "Fluoroquinolones: Spectrum (P. aeruginosa)",
    "questionText": "Ciprofloxacin, Levofloxacin, and Delafloxacin all have activity against *P. aeruginosa*. Which major respiratory fluoroquinolone is *not* active against *P. aeruginosa*?",
    "options": [
      {"text": "Ciprofloxacin", "explanation": "This is incorrect. Ciprofloxacin is strongly active against *P. aeruginosa*."},
      {"text": "Levofloxacin", "explanation": "This is incorrect. Levofloxacin is active against *P. aeruginosa*."},
      {"text": "Moxifloxacin", "explanation": "This is correct. Moxifloxacin is generally not active against *P. aeruginosa*."},
      {"text": "Delafloxacin", "explanation": "This is incorrect. Delafloxacin is active against *P. aeruginosa*."},
      {"text": "Ofloxacin", "explanation": "This is incorrect. Ofloxacin lacks reliable *P. aeruginosa* coverage."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0046.jpg"
  },
  {
    "id": 40,
    "category": "Fluoroquinolones: Resistance",
    "questionText": "The *main mechanism* of high-level FQ resistance involves chromosomal modifications, particularly spontaneous point mutations in the genes encoding which components?",
    "options": [
      {"text": "Ribosomal subunits (16S and 23S)", "explanation": "This is incorrect. This is the target for protein synthesis inhibitors."},
      {"text": "DHPS and DHFR", "explanation": "This is incorrect. This is the target for folate inhibitors."},
      {"text": "DNA gyrase (*gyrA*) and Topoisomerase IV (*parC*)", "explanation": "This is correct. Chromosomal modifications, such as point mutations, in the genes encoding the FQ binding regions of DNA gyrase and Topoisomerase IV are the main mechanisms of FQ resistance and confer high-level resistance."},
      {"text": "Penicillin-binding proteins (PBPs)", "explanation": "This is incorrect. This is the target for beta-lactams."},
      {"text": "Qnr proteins and acetyltransferases", "explanation": "This is incorrect. These are plasmid-mediated mechanisms which confer low-level resistance."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0046.jpg"
  },
  {
    "id": 41,
    "category": "Fluoroquinolones: Resistance",
    "questionText": "What two plasmid-mediated mechanisms confer *low-level* resistance to FQs?",
    "options": [
      {"text": "Efflux pumps and porin deletion", "explanation": "This is incorrect. These are generally chromosomal mutations that confer high-level resistance."},
      {"text": "Tendon rupture and peripheral neuropathy", "explanation": "This is incorrect. These are adverse effects."},
      {"text": "Qnr protein protection and acetylation by acetyltransferase", "explanation": "This is correct. Plasmid transfer genes encoding the Qnr topoisomerase protection protein and acetyltransferases that modify the drug are the mechanisms that confer low-level FQ resistance."},
      {"text": "Decatenation and supercoiling", "explanation": "This is incorrect. These are mechanisms of the drug's action on DNA."},
      {"text": "Inhibition of DHPS and DHFR", "explanation": "This is incorrect. This is the mechanism of folate inhibitors."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0046.jpg"
  },
  {
    "id": 42,
    "category": "Fluoroquinolones: Adverse Effects",
    "questionText": "Which serious, disabling, and potentially permanent class adverse effect requires FQs to be avoided in patients receiving glucocorticoids?",
    "options": [
      {"text": "Peripheral neuropathy", "explanation": "This is incorrect. While permanent, glucocorticoids do not increase the risk of this AE."},
      {"text": "QTc interval prolongation", "explanation": "This is incorrect. This is an electrical effect, not musculoskeletal."},
      {"text": "Tendon inflammation/rupture", "explanation": "This is correct. Concomitant use of FQs and glucocorticoids significantly increases the risk of tendon inflammation (tendinitis) and rupture, which is a U.S. Boxed Warning."},
      {"text": "CNS effects (psychosis)", "explanation": "This is incorrect. Glucocorticoids do not specifically increase this FQ AE risk."},
      {"text": "Hemolytic anemia", "explanation": "This is incorrect. Hemolytic anemia is primarily linked to G6PD deficiency."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0050.jpg"
  },
  {
    "id": 43,
    "category": "Fluoroquinolones: Drug Interactions",
    "questionText": "A patient on ciprofloxacin develops increased blood levels of theophylline, increasing the risk of seizures. What is the mechanism of this drug-drug interaction?",
    "options": [
      {"text": "Ciprofloxacin inhibits CYP1A2, which metabolizes theophylline.", "explanation": "This is correct. Ciprofloxacin inhibits CYP1A2, and theophylline is a major substrate of this enzyme. Inhibition reduces theophylline clearance, increasing plasma levels and the risk of toxicity (e.g., seizures)."},
      {"text": "Ciprofloxacin enhances the absorption of theophylline.", "explanation": "This is incorrect. The interaction is metabolic, not based on absorption."},
      {"text": "Ciprofloxacin inhibits theophylline's renal tubular secretion.", "explanation": "This is incorrect. While both are renally eliminated, the primary mechanism is metabolic inhibition."},
      {"text": "Ciprofloxacin and theophylline compete for Topoisomerase IV.", "explanation": "This is incorrect. This is not the target of theophylline."},
      {"text": "Ciprofloxacin is eliminated renally, and theophylline is eliminated hepatically.", "explanation": "This is incorrect. This fact is true but doesn't explain the interaction."},
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L126_page-0050.jpg"
  },
  {
    "id": 44,
    "category": "Fluoroquinolones: Adverse Effects",
    "questionText": "FQ use is associated with a range of CNS effects. Which serious psychiatric adverse effects are listed as part of the FDA warnings?",
    "options": [
      {"text": "Aphasia and dysarthria", "explanation": "This is incorrect. These are neurological deficits, not specific psychiatric AEs listed."},
      {"text": "Psychosis, depression, and disorientation/agitation", "explanation": "This is correct. Toxic psychosis, delirium, disorientation, agitation, depression, and suicidal thoughts are specific mental health adverse reactions associated with FQs."},
      {"text": "Hyperesthesia and ataxia", "explanation": "This is incorrect. These are sensory/motor AEs."},
      {"text": "Irreversible blindness", "explanation": "This is incorrect. This is not a specific FQ AE."},
      {"text": "Megaloblastic anemia", "explanation": "This is incorrect. This is a toxicity of trimethoprim."},
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0048.jpg"
  },
  {
    "id": 45,
    "category": "Fluoroquinolones: Adverse Effects",
    "questionText": "FQ use is associated with potentially permanent nerve damage, often presenting as numbness or tingling in the hands and feet. This serious adverse effect is referred to as what?",
    "options": [
      {"text": "Tendonitis", "explanation": "This is incorrect. This affects tendons, not nerves."},
      {"text": "Myalgia", "explanation": "This is incorrect. This affects muscles, not nerves."},
      {"text": "Peripheral neuropathy", "explanation": "This is correct. FQs are associated with disabling and potentially permanent peripheral neuropathy (nerve damage), often presenting as tingling, numbness, or pain in the extremities."},
      {"text": "Central nervous system (CNS) toxicity", "explanation": "This is incorrect. Peripheral neuropathy is a specific type of toxicity distinct from CNS effects."},
      {"text": "Agranulocytosis", "explanation": "This is incorrect. This is a hematopoietic toxicity."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0048.jpg"
  },
  {
    "id": 46,
    "category": "Fluoroquinolones: Adverse Effects",
    "questionText": "FQ use is contraindicated in patients with myasthenia gravis due to the risk of exacerbation, which can lead to which life-threatening event?",
    "options": [
      {"text": "Aortic dissection", "explanation": "This is incorrect. This is a separate vascular risk."},
      {"text": "Severe hypoglycemia", "explanation": "This is incorrect. This is a separate metabolic risk."},
      {"text": "Respiratory depression/ventilatory support", "explanation": "This is correct. FQs can exacerbate myasthenia gravis (an autoimmune disease that causes muscle weakness), increasing muscle weakness to the point of potentially causing respiratory failure or death."},
      {"text": "Irreversible peripheral neuropathy", "explanation": "This is incorrect. While FQs cause peripheral neuropathy, the primary risk in MG is respiratory muscle failure."},
      {"text": "Seizures", "explanation": "This is incorrect. Seizures are a separate CNS risk."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0048.jpg"
  },
  {
    "id": 47,
    "category": "Fluoroquinolones: Adverse Effects",
    "questionText": "All FQs should be used cautiously in patients with underlying proarrhythmic conditions, due to the risk of exacerbating which adverse effect recorded on EKG?",
    "options": [
      {"text": "ST segment elevation", "explanation": "This is incorrect. This indicates ischemia."},
      {"text": "Atrial fibrillation", "explanation": "This is incorrect. FQs do not directly cause AFib."},
      {"text": "QTc interval prolongation", "explanation": "This is correct. All FQs are associated with QTc interval prolongation (due to their effect on cardiac potassium channels), which increases the risk of ventricular arrhythmia, especially torsades de pointes."},
      {"text": "Bilateral bundle branch block", "explanation": "This is incorrect. This is a conduction defect."},
      {"text": "Aortic dissection", "explanation": "This is incorrect. This is a separate vascular risk."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0048.jpg"
  },
  {
    "id": 48,
    "category": "Fluoroquinolones: Adverse Effects",
    "questionText": "Diabetic patients taking FQs must be monitored for which two types of glucose dysregulation?",
    "options": [
      {"text": "Serious hypoglycemia and hyperglycemia", "explanation": "This is correct. FQs have been associated with dysglycemia, including serious hypoglycemia (sometimes leading to coma) and hyperglycemia in diabetic patients."},
      {"text": "Serious hypoglycemia and glucose hyper-excretion", "explanation": "This is incorrect. Glucose hyper-excretion is characteristic of SGLT2 inhibitors."},
      {"text": "Insulin resistance and hyperketonemia", "explanation": "This is incorrect. These are consequences of poorly controlled diabetes, not specific FQ side effects."},
      {"text": "Lactic acidosis and renal failure", "explanation": "This is incorrect. Lactic acidosis is a rare AE of linezolid."},
      {"text": "Hypocalcemia and hyperphosphatemia", "explanation": "This is incorrect. This is not a specific FQ AE."},
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L126_page-0048.jpg"
  },
  {
    "id": 49,
    "category": "Fluoroquinolones: Clinical Use (Absorption)",
    "questionText": "FQs are widely distributed in tissues, including phagocytic cells (macrophages/neutrophils). What clinical relevance does this have?",
    "options": [
      {"text": "It requires the drug to be administered once daily.", "explanation": "This is incorrect. Once-daily dosing is due to their long half-lives and PK/PD profile."},
      {"text": "It causes blue-gray discoloration of the skin.", "explanation": "This is incorrect. This is a toxicity of minocycline."},
      {"text": "It makes them effective against infections caused by intracellular pathogens like *Legionella*.", "explanation": "This is correct. FQs concentrate in macrophages and neutrophils, making them highly effective against intracellular pathogens such as *Legionella*, *Chlamydia*, and *Rickettsia*."},
      {"text": "It increases the risk of irreversible peripheral neuropathy.", "explanation": "This is incorrect. This is a separate adverse effect."},
      {"text": "It makes them the drug of choice for *C. difficile* infection.", "explanation": "This is incorrect. FQs increase the risk of *C. difficile* infection."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0041.jpg"
  },
  {
    "id": 50,
    "category": "Fluoroquinolones: Clinical Use (Bioterrorism)",
    "questionText": "FQs are a drug of choice for the treatment of which specific bioterrorism-related infection?",
    "options": [
      {"text": "Smallpox", "explanation": "This is incorrect. Smallpox is a virus."},
      {"text": "Ebola", "explanation": "This is incorrect. Ebola is a virus."},
      {"text": "Anthrax (*Bacillus anthracis*)", "explanation": "This is correct. FQs, particularly ciprofloxacin, are a drug of choice for the treatment of anthrax (and prophylaxis following inhalational exposure)."},
      {"text": "Botulism", "explanation": "This is incorrect. Botulism is treated with antitoxin."},
      {"text": "Tuberculosis (MDR-TB)", "explanation": "This is incorrect. While used for MDR-TB, anthrax is the more specific bioterrorism-related indication."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0047.jpg"
  },
  {
    "id": 51,
    "category": "Fluoroquinolones: Clinical Use (Topical)",
    "questionText": "FQs are available topically for use in which two infection sites?",
    "options": [
      {"text": "Intra-abdominal and Pelvic", "explanation": "This is incorrect. These require systemic administration."},
      {"text": "Central Nervous System (CNS) and Bone", "explanation": "This is incorrect. These require systemic administration."},
      {"text": "Ophthalmic and Otic", "explanation": "This is correct. Several FQs are formulated for topical use in ophthalmic (eye drops) and otic (ear drops) preparations for local infections."},
      {"text": "Vaginal and Rectal", "explanation": "This is incorrect. Clindamycin is available for vaginal use."},
      {"text": "Pulmonary and Skin", "explanation": "This is incorrect. Pulmonary requires inhalation (e.g., tobramycin)."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0047.jpg"
  },
  {
    "id": 52,
    "category": "Fluoroquinolones: Resistance",
    "questionText": "Which of the two plasmid-mediated resistance mechanisms confers *low-level* resistance to FQs?",
    "options": [
      {"text": "Tendon rupture and peripheral neuropathy", "explanation": "This is incorrect. These are adverse effects."},
      {"text": "Decatenation and supercoiling", "explanation": "This is incorrect. These are mechanisms of the drug's action on DNA."},
      {"text": "Point mutations in DNA gyrase and Topoisomerase IV", "explanation": "This is incorrect. These are chromosomal modifications conferring high-level resistance."},
      {"text": "Qnr protein protection and acetylation by acetyltransferase", "explanation": "This is correct. Plasmid transfer genes encoding the Qnr topoisomerase protection protein and acetyltransferases that modify the FQ are the mechanisms that confer low-level FQ resistance."},
      {"text": "Inhibition of DHPS and DHFR", "explanation": "This is incorrect. This is the mechanism of folate inhibitors."},
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L126_page-0046.jpg"
  },
  {
    "id": 53,
    "category": "Fluoroquinolones: Adverse Effects",
    "questionText": "The FDA advises FQs should only be used as alternatives, never first-line, for uncomplicated infections (sinusitis, bronchitis, UTI). Why?",
    "options": [
      {"text": "FQs are bacteriostatic and require co-administration with other agents.", "explanation": "This is incorrect. FQs are bactericidal."},
      {"text": "The risks of permanent side effects outweigh the benefits when other, safer options exist.", "explanation": "This is correct. FQs carry boxed warnings for serious, potentially permanent side effects (tendon rupture, neuropathy, CNS effects), making the risk unacceptable for common infections where safer, effective alternatives are available."},
      {"text": "FQs cause a high incidence of irreversible megaloblastic anemia.", "explanation": "This is incorrect. Megaloblastic anemia is a risk of trimethoprim."},
      {"text": "FQs stimulate the growth of *P. aeruginosa* in the upper respiratory tract.", "explanation": "This is incorrect. Sulfonamides stimulate the growth of *Rickettsia*."},
      {"text": "Resistance develops too rapidly during therapy for uncomplicated infections.", "explanation": "This is incorrect. While resistance develops, the primary reason is the serious AE risk."},
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0046.jpg"
  },
  {
    "id": 54,
    "category": "Fluoroquinolones: Spectrum",
    "questionText": "Ciprofloxacin has excellent activity against which main group of bacteria, setting it apart from the respiratory FQs?",
    "options": [
      {"text": "Gram-positive cocci (including MRSA)", "explanation": "This is incorrect. Delafloxacin covers MRSA."},
      {"text": "Aerobic Gram-negative bacteria (including *P. aeruginosa*)", "explanation": "This is correct. Ciprofloxacin's primary activity is against aerobic Gram-negative bacteria, including *P. aeruginosa*."},
      {"text": "Atypical bacteria (*Mycoplasma*, *Chlamydia*)", "explanation": "This is incorrect. This is the hallmark of the respiratory FQs."},
      {"text": "Anaerobic bacteria (*B. fragilis*)", "explanation": "This is incorrect. Moxifloxacin has the broadest anaerobic coverage."},
      {"text": "Spirochetes (*Borrelia* spp)", "explanation": "This is incorrect. Doxycycline is the drug of choice for Lyme disease."},
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0054.jpg"
  },
  {
    "id": 55,
    "category": "Fluoroquinolones: Mechanism of Action",
    "questionText": "The interference of Topoisomerase IV is responsible for blocking which aspect of bacterial cell division?",
    "options": [
      {"text": "DNA supercoiling", "explanation": "This is incorrect. DNA gyrase is primarily responsible for supercoiling."},
      {"text": "Peptide bond formation", "explanation": "This is incorrect. This is the function of peptidyl transferase (50S ribosome)."},
      {"text": "Decatenation (separation of daughter cells)", "explanation": "This is correct. Topoisomerase IV's function is decatenation, the separation of the linked daughter chromosomes during cell division, which FQs inhibit."},
      {"text": "PABA incorporation", "explanation": "This is incorrect. This is the function of DHPS."},
      {"text": "mRNA misreading", "explanation": "This is incorrect. This is the effect of aminoglycosides."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0044.jpg"
  },
  {
    "id": 56,
    "category": "Fluoroquinolones: Adverse Effects",
    "questionText": "Peripheral neuropathy caused by FQs is a major concern because it can lead to what outcome?",
    "options": [
      {"text": "Irreversible nerve damage", "explanation": "This is correct. Peripheral neuropathy is a serious adverse effect of FQs that can occur soon after therapy initiation and is potentially permanent and irreversible."},
      {"text": "Fatal hepatotoxicity", "explanation": "This is incorrect. This is a separate, non-neuropathic toxicity (e.g., associated with trovafloxacin, withdrawn from market)."},
      {"text": "Acute kidney injury", "explanation": "This is incorrect. This is a separate, non-neuropathic toxicity."},
      {"text": "Stevens-Johnson syndrome", "explanation": "This is incorrect. This is a severe hypersensitivity reaction."},
      {"text": "Aortic dissection", "explanation": "This is incorrect. This is a separate vascular risk."},
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L126_page-0048.jpg"
  },
  {
    "id": 57,
    "category": "Fluoroquinolones: Pharmacokinetics (Intracellular)",
    "questionText": "FQs distribute widely in tissues and achieve high concentrations in macrophages and neutrophils. What clinical relevance does this have?",
    "options": [
      {"text": "It requires the drug to be administered once daily.", "explanation": "This is incorrect. This is due to their long half-lives and PK/PD profile."},
      {"text": "It makes them ineffective against intracellular pathogens.", "explanation": "This is incorrect. This is why they *are* effective against intracellular pathogens."},
      {"text": "It makes them effective against infections caused by intracellular pathogens like *Legionella*.", "explanation": "This is correct. FQs accumulate in phagocytic cells, making them highly effective against infections caused by intracellular pathogens such as *Legionella*, *Chlamydia*, and *Rickettsia*."},
      {"text": "It significantly increases the risk of tendon rupture.", "explanation": "This is incorrect. This is a separate adverse effect."},
      {"text": "It is the reason they are contraindicated in pregnancy.", "explanation": "This is incorrect. The contraindication in pregnancy is due to animal studies on joint malformation."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0041.jpg"
  },
  {
    "id": 58,
    "category": "Fluoroquinolones: Clinical Use (Resistance)",
    "questionText": "FQs are the only oral antibiotics effective for treating which specific gram-negative aerobic pathogen?",
    "options": [
      {"text": "*E. coli* UTI", "explanation": "This is incorrect. Many oral drugs treat *E. coli* UTIs (e.g., TMP-SMX)."},
      {"text": "*P. aeruginosa*", "explanation": "This is correct. Fluoroquinolones (like ciprofloxacin and levofloxacin) are the only oral antibiotics effective against *Pseudomonas aeruginosa*."},
      {"text": "*H. influenzae*", "explanation": "This is incorrect. Many oral drugs treat *H. influenzae*."},
      {"text": "*M. pneumoniae*", "explanation": "This is incorrect. Macrolides are first-line for *M. pneumoniae*."},
      {"text": "*C. difficile*", "explanation": "This is incorrect. FQs increase the risk of *C. difficile* infection."},
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L126_page-0054.jpg"
  },
  {
    "id": 59,
    "category": "Fluoroquinolones: Adverse Effects (CNS)",
    "questionText": "Which FQ toxicity is a serious CNS adverse effect that increases the risk of seizures and is listed as part of the FDA warnings?",
    "options": [
      {"text": "Peripheral neuropathy", "explanation": "This is incorrect. Peripheral neuropathy is a nervous system effect, but the specific serious *CNS* risk is seizures."},
      {"text": "Aortic dissection", "explanation": "This is incorrect. This is a separate vascular risk."},
      {"text": "Increased intracranial pressure", "explanation": "This is correct. Increased intracranial pressure (pseudotumor cerebri) is listed under CNS effects and can be associated with seizures."},
      {"text": "Hypoglycemia", "explanation": "This is incorrect. This is a separate metabolic risk."},
      {"text": "Tendon rupture", "explanation": "This is incorrect. This is a musculoskeletal risk."},
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L126_page-0048.jpg"
  },
  {
    "id": 60,
    "category": "Fluoroquinolones: Clinical Use (Gonorrhea)",
    "questionText": "What is the current recommendation for FQ use in treating gonorrhea?",
    "options": [
      {"text": "FQs are generally not recommended due to widespread acquired resistance.", "explanation": "This is correct. FQs are generally not recommended for *N. gonorrhoeae* due to widespread acquired resistance."},
      {"text": "Ciprofloxacin is the IM drug of choice.", "explanation": "This is incorrect. Ceftriaxone is the IM drug of choice."},
      {"text": "Moxifloxacin is the oral drug of choice.", "explanation": "This is incorrect. FQs are generally avoided."},
      {"text": "FQs should be used in combination with trimethoprim.", "explanation": "This is incorrect. This combination is not used for gonorrhea."},
      {"text": "FQs are only used for pharyngeal gonorrhea infections.", "explanation": "This is incorrect. FQs are generally not recommended for any gonorrheal infections."},
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L126_page-0047.jpg"
  }
];